Lexeo Therapeutics Inc. C... (LXEO)
NASDAQ: LXEO
· Real-Time Price · USD
4.66
-0.13 (-2.71%)
At close: Aug 15, 2025, 3:48 PM
Lexeo Therapeutics Common Stock Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 531K | 568K | 653.55K | 653.55K | 122.55K | 85.55K |
Cost of Revenue | 496K | 972K | 1.46M | 1.92M | 1.87M | 1.84M | 1.35M | 893K | 798.23K | 358K | 358K | 358K | 6.7K |
Gross Profit | -496K | -972K | -1.46M | -1.92M | -1.87M | -1.84M | -1.35M | -362K | -230.23K | 295.55K | 295.55K | -235.45K | 78.85K |
Operating Income | -116.28M | -105.77M | -93.36M | -82.09M | -72.51M | -68.51M | -68.73M | -65.94M | -67.28M | -60.51M | -45.31M | -27.83M | -12.52M |
Interest Income | 7.12M | 7.58M | 7.19M | 5.59M | 3.83M | 2.87M | 2.44M | 2.41M | 2M | 1.33M | 650.28K | 194.28K | 17.28K |
Pretax Income | -109.31M | -98.33M | -86.6M | -77.22M | -69.42M | -66.39M | -66.78M | -63.73M | -65.43M | -59.28M | -44.7M | -27.64M | -12.5M |
Net Income | -109.31M | -98.33M | -86.6M | -77.22M | -69.42M | -66.39M | -66.78M | -63.73M | -65.43M | -59.28M | -44.7M | -27.64M | -12.5M |
Selling & General & Admin | 40.76M | 31.68M | 29.42M | 24.33M | 20.08M | 15.38M | 12.43M | 12.05M | 12.39M | 11.99M | 8.18M | 5.53M | 2.45M |
Research & Development | 75.52M | 74.09M | 63.94M | 57.76M | 52.43M | 53.13M | 56.31M | 54.42M | 55.45M | 49.16M | 37.78M | 22.41M | 10.15M |
Other Expenses | n/a | n/a | 6K | 6K | 3K | -1K | -7K | -7K | -4K | n/a | n/a | n/a | n/a |
Operating Expenses | 116.28M | 105.77M | 93.36M | 82.09M | 72.51M | 68.51M | 68.73M | 66.47M | 67.85M | 61.16M | 45.96M | 27.95M | 12.6M |
Interest Expense | 128K | 137K | 157K | 174K | 192K | 205K | 209K | 186K | 142K | 92K | 38K | 9K | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 116.28M | 105.77M | 93.36M | 82.09M | 72.51M | 68.51M | 68.73M | 66.47M | 67.85M | 61.16M | 45.97M | 27.95M | 12.6M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -2 | -2 | -2 | -2 |
Shares Outstanding (Basic) | 33.11M | 33.08M | 33.06M | 33M | 27.98M | 27.31M | 25.17M | 25.17M | 25.17M | 25.17M | 25.17M | 25.17M | 26.65M |
Shares Outstanding (Diluted) | 33.11M | 33.08M | 33.06M | 33M | 27.98M | 27.31M | 25.17M | 25.17M | 25.17M | 25.17M | 25.17M | 25.17M | 26.65M |
EPS (Basic) | -3.34 | -3.12 | -2.82 | -2.73 | -2.62 | -2.59 | -2.65 | -2.53 | -2.6 | -2.33 | -1.75 | -1.07 | -0.47 |
EPS (Diluted) | -3.34 | -3.12 | -2.82 | -2.73 | -2.62 | -2.59 | -2.65 | -2.53 | -2.6 | -2.33 | -1.75 | -1.07 | -0.47 |
EBITDA | -109.51M | -98.56M | -86.81M | -77.47M | -67.94M | -65.62M | -66.05M | -63.13M | -64.74M | -58.41M | -44.33M | -27.65M | -12.51M |
EBIT | -109.19M | -98.22M | -86.44M | -77.04M | -69.23M | -66.19M | -66.57M | -63.54M | -65.29M | -59.2M | -44.68M | -27.65M | -12.52M |
Depreciation & Amortization | 2.03M | 2M | 1.97M | 1.92M | 1.87M | 1.84M | 1.8M | 1.68M | 1.23M | 793.7K | 348.7K | 6.7K | 6.7K |